Acadia Pharmaceuticals (ACAD) EPS (Weighted Average and Diluted) (2010 - 2026)
Acadia Pharmaceuticals' quarterly EPS (Weighted Average and Diluted) came in at $0.02 in Q1 2026, down 81.82% year-on-year from $0.11 in Q1 2025, and down 98.76% quarter-over-quarter from $1.61 in Q4 2025.
Acadia Pharmaceuticals has reported EPS (Weighted Average and Diluted) for 10 years, with the latest figure at $0.02 in Q1 2026.
- For the quarter ending Q1 2026, EPS (Weighted Average and Diluted) fell 81.82% year-over-year to $0.02; the trailing twelve-month figure through Mar 2026 stood at $2.21 (up 61.31% YoY), and the FY2025 full-year result was $2.3, up 69.12% from the prior year.
- EPS (Weighted Average and Diluted) for Q1 2026 stood at $0.02, down from $1.61 in the prior quarter.
- The five-year high for EPS (Weighted Average and Diluted) was $1.61 in Q4 2025, with the low at -$0.7 in Q1 2022.
- Average EPS (Weighted Average and Diluted) over 5 years is $0.12, with a median of $0.1 recorded in 2024.
- Year-over-year, EPS (Weighted Average and Diluted) tumbled 135.29% in 2023 and soared 1900.0% in 2024.
- Tracing ACAD's EPS (Weighted Average and Diluted) over 5 years: stood at -$0.26 in 2022, then soared by 207.69% to $0.28 in 2023, then jumped by 207.14% to $0.86 in 2024, then surged by 87.21% to $1.61 in 2025, then plunged by 98.76% to $0.02 in 2026.
- The last three EPS (Weighted Average and Diluted) figures came in at $0.02 (Q1 2026), $1.61 (Q4 2025), and $0.42 (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EPS (Weighted Avg. Diluted) (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - | -4.43 |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - | - |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn | 3,086.42 |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - | - |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - | 0.00 |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn | 4.02 |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn | 6.75 |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn | 1.51 |
| 10 | Acadia Pharmaceuticals | 3.69 Bn | 2.84 Bn | 243.27 Mn | 0.02 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 0.02 |
| Dec 31, 2025 | 1.61 |
| Sep 30, 2025 | 0.42 |
| Jun 30, 2025 | 0.16 |
| Mar 31, 2025 | 0.11 |
| Dec 31, 2024 | 0.86 |
| Sep 30, 2024 | 0.20 |
| Jun 30, 2024 | 0.20 |
| Mar 31, 2024 | 0.10 |
| Dec 31, 2023 | 0.28 |
| Sep 30, 2023 | -0.40 |
| Jun 30, 2023 | 0.01 |
| Mar 31, 2023 | -0.27 |
| Dec 31, 2022 | -0.26 |
| Sep 30, 2022 | -0.17 |
| Jun 30, 2022 | -0.21 |
| Mar 31, 2022 | -0.70 |
| Dec 31, 2021 | -0.27 |
| Sep 30, 2021 | -0.09 |
| Jun 30, 2021 | -0.27 |
| Mar 31, 2021 | -0.42 |
| Dec 31, 2020 | -422.99 |
| Dec 31, 2012 | -0.12 |
| Dec 31, 2011 | -0.10 |
| Dec 31, 2010 | 0.75 |